AnaptysBio (ANAB) Financials

$20.73 -0.46 (-2.17%)

Closing price 04:00 PM Eastern

Extended Trading

$20.71 -0.02 (-0.10%)

As of 05:06 PM Eastern

Annual Income Statements for AnaptysBio

This table shows AnaptysBio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-129	-164	-145
Consolidated Net Income / (Loss)	-129	-164	-145
Net Income / (Loss) Continuing Operations	-129	-164	-145
Total Pre-Tax Income	-129	-164	-145
Total Operating Income	-115	-164	-115
Total Gross Profit	10	17	91
Total Revenue	10	17	91
Operating Revenue	10	17	91
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	125	182	206
Selling, General & Admin Expense	37	42	42
Research & Development Expense	89	140	164
Total Other Income / (Expense), net	-14	0.79	-30
Interest Expense	21	18	50
Interest & Investment Income	7.55	19	20
Other Income / (Expense), net	0.01	-0.00	0.01
Income Tax Expense	0.02	-0.00	0.00
Basic Earnings per Share	($4.57)	($6.08)	($5.12)
Weighted Average Basic Shares Outstanding	28.17M	26.92M	28.38M
Diluted Earnings per Share	($4.57)	($6.08)	($5.12)
Weighted Average Diluted Shares Outstanding	28.17M	26.92M	28.38M
Weighted Average Basic & Diluted Shares Outstanding	27.93M	26.76M	30.67M

This table shows AnaptysBio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-34	-26	-44	-40	-37	-42	-44	-47	-33	-22
Consolidated Net Income / (Loss)	-34	-26	-44	-40	-37	-42	-44	-47	-33	-22
Net Income / (Loss) Continuing Operations	-34	-26	-44	-40	-37	-42	-44	-47	-33	-22
Total Pre-Tax Income	-34	-26	-44	-40	-37	-42	-44	-47	-33	-22
Total Operating Income	-30	-26	-44	-40	-38	-42	-42	-40	-23	-9.67
Total Gross Profit	1.29	6.81	1.37	3.46	3.32	9.01	7.18	11	30	43
Total Revenue	1.29	6.81	1.37	3.46	3.32	9.01	7.18	11	30	43
Operating Revenue	1.29	6.81	1.37	3.46	3.32	9.01	7.18	11	30	43
Total Operating Expenses	31	33	46	44	41	51	49	51	53	53
Selling, General & Admin Expense	8.86	9.41	11	11	10	10	12	9.30	11	10
Research & Development Expense	22	23	35	33	31	41	37	42	42	43
Total Other Income / (Expense), net	-3.87	-0.42	0.15	0.30	0.42	-0.08	-1.74	-6.33	-10	-12
Interest Expense	6.14	4.25	4.34	4.36	4.43	4.96	6.32	11	15	17
Interest & Investment Income	2.26	3.84	4.49	4.65	4.85	4.88	4.58	4.62	5.32	5.26
Other Income / (Expense), net	0.00	-0.00	-0.00	0.00	0.00	-0.00	-0.00	0.00	-0.01	0.02
Basic Earnings per Share	($1.18)	($0.93)	($1.58)	($1.50)	($1.41)	($1.59)	($1.64)	($1.71)	($1.14)	($0.63)
Weighted Average Basic Shares Outstanding	28.29M	28.17M	27.95M	26.63M	26.55M	26.92M	26.80M	27.36M	28.89M	28.38M
Diluted Earnings per Share	($1.18)	($0.93)	($1.58)	($1.50)	($1.41)	($1.59)	($1.64)	($1.71)	($1.14)	($0.63)
Weighted Average Diluted Shares Outstanding	28.29M	28.17M	27.95M	26.63M	26.55M	26.92M	26.80M	27.36M	28.89M	28.38M
Weighted Average Basic & Diluted Shares Outstanding	28.43M	27.93M	26.49M	26.55M	26.58M	26.76M	27.32M	27.45M	30.43M	30.67M

This table details how cash moves in and out of AnaptysBio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-424	-35	87
Net Cash From Operating Activities	-74	-121	-135
Net Cash From Continuing Operating Activities	-74	-121	-135
Net Income / (Loss) Continuing Operations	-129	-164	-145
Consolidated Net Income / (Loss)	-129	-164	-145
Depreciation Expense	0.68	0.65	0.61
Amortization Expense	1.66	1.72	1.79
Non-Cash Adjustments To Reconcile Net Income	45	35	40
Changes in Operating Assets and Liabilities, net	7.38	5.11	-32
Net Cash From Investing Activities	-395	145	95
Net Cash From Continuing Investing Activities	-395	145	95
Purchase of Property, Plant & Equipment	-0.36	-0.81	-0.36
Purchase of Investments	-803	-304	-380
Sale and/or Maturity of Investments	408	449	476
Net Cash From Financing Activities	44	-59	127
Net Cash From Continuing Financing Activities	44	-59	127
Repurchase of Common Equity	0.00	-50	-0.95
Issuance of Common Equity	12	2.47	6.47
Other Financing Activities, net	32	-12	122
Cash Interest Paid	0.00	0.00	42

This table details how cash moves in and out of AnaptysBio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-13	13	23	-59	-8.91	9.67	18	18	120	-69
Net Cash From Operating Activities	-18	-11	-25	-25	-36	-34	-37	-21	-10	-67
Net Cash From Continuing Operating Activities	-18	-11	-25	-25	-36	-34	-37	-21	-10	-67
Net Income / (Loss) Continuing Operations	-34	-26	-44	-40	-37	-42	-44	-47	-33	-22
Consolidated Net Income / (Loss)	-34	-26	-44	-40	-37	-42	-44	-47	-33	-22
Depreciation Expense	0.17	0.18	0.17	0.16	0.16	0.17	0.16	0.15	0.14	0.15
Amortization Expense	-0.37	1.21	0.43	0.42	0.43	0.44	0.44	0.44	0.45	0.46
Non-Cash Adjustments To Reconcile Net Income	13	8.19	11	8.94	9.16	6.33	13	14	18	-5.28
Changes in Operating Assets and Liabilities, net	2.96	6.15	8.19	4.91	-8.92	0.93	-7.16	11	4.32	-40
Net Cash From Investing Activities	-32	21	85	-20	31	49	69	-2.44	59	-29
Net Cash From Continuing Investing Activities	-32	21	85	-20	31	49	69	-2.44	59	-29
Purchase of Property, Plant & Equipment	-0.05	-0.18	-0.18	-0.19	-0.16	-0.28	-0.03	-0.03	-0.04	-0.26
Purchase of Investments	-180	-128	-49	-119	-70	-66	-59	-149	-51	-121
Sale and/or Maturity of Investments	148	149	134	99	101	116	128	147	110	92
Net Cash From Financing Activities	37	1.95	-38	-13	-3.07	-5.16	-14	42	71	28
Net Cash From Continuing Financing Activities	37	1.95	-38	-13	-3.07	-5.16	-14	42	71	28
Repurchase of Common Equity	-	-	-38	-12	-	-	0.00	-	-0.37	-0.58
Issuance of Common Equity	2.70	3.42	1.27	0.78	0.16	0.26	0.81	0.98	4.13	0.56
Other Financing Activities, net	35	-1.76	-1.27	-1.80	-3.23	-5.47	-14	41	68	27

This table presents AnaptysBio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	610	452	484
Total Current Assets	447	407	432
Cash & Equivalents	71	36	123
Short-Term Investments	370	355	262
Accounts Receivable	1.42	6.85	41
Prepaid Expenses	4.55	9.08	5.74
Plant, Property, & Equipment, net	2.09	2.10	1.85
Total Noncurrent Assets	161	43	50
Long-Term Investments	143	27	35
Other Noncurrent Operating Assets	18	16	15
Total Liabilities & Shareholders' Equity	610	452	484
Total Liabilities	348	364	413
Total Current Liabilities	26	37	45
Accounts Payable	2.78	4.70	4.00
Accrued Expenses	22	31	40
Other Current Liabilities	1.64	1.78	1.93
Total Noncurrent Liabilities	322	327	368
Other Noncurrent Operating Liabilities	322	327	368
Total Equity & Noncontrolling Interests	262	88	71
Total Preferred & Common Equity	262	88	71
Preferred Stock	0.00	0.00	0.00
Total Common Equity	262	88	71
Common Stock	718	703	830
Retained Earnings	-450	-614	-759
Accumulated Other Comprehensive Income / (Loss)	-5.25	-0.80	0.31

This table presents AnaptysBio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	619	552	517	487	406	427	493
Total Current Assets	450	437	439	428	372	367	449
Cash & Equivalents	59	95	35	26	54	72	192
Short-Term Investments	384	337	394	387	301	279	239
Accounts Receivable	1.18	1.52	3.18	3.27	7.09	9.01	12
Prepaid Expenses	6.30	4.48	5.87	12	11	7.54	6.37
Plant, Property, & Equipment, net	1.97	1.98	2.02	2.25	1.95	1.83	1.73
Total Noncurrent Assets	166	113	77	57	31	58	43
Long-Term Investments	148	95	59	40	15	43	28
Other Noncurrent Operating Assets	19	18	17	17	16	16	15
Total Liabilities & Shareholders' Equity	619	552	517	487	406	427	493
Total Liabilities	341	361	369	367	358	417	409
Total Current Liabilities	21	36	42	39	32	40	44
Accounts Payable	3.01	3.17	4.76	6.52	4.58	4.89	3.59
Accrued Expenses	16	31	35	31	26	34	38
Other Current Liabilities	1.60	1.67	1.71	1.74	1.81	1.85	1.89
Total Noncurrent Liabilities	320	325	327	328	326	377	365
Other Noncurrent Operating Liabilities	320	325	327	328	326	377	365
Total Equity & Noncontrolling Interests	278	191	148	120	48	9.88	84
Total Preferred & Common Equity	278	191	148	120	48	9.88	84
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	278	191	148	120	48	9.88	84
Common Stock	708	689	687	695	706	715	821
Retained Earnings	-424	-495	-535	-572	-658	-705	-738
Accumulated Other Comprehensive Income / (Loss)	-6.01	-3.27	-3.61	-2.35	-0.62	-0.42	0.76

This table displays calculated financial ratios and metrics derived from AnaptysBio's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	-83.72%	66.78%	432.03%
EBITDA Growth	-106.28%	-43.64%	30.55%
EBIT Growth	-102.80%	-42.79%	30.09%
NOPAT Growth	-102.69%	-42.77%	30.08%
Net Income Growth	-122.72%	-27.11%	11.24%
EPS Growth	-116.59%	-33.04%	15.79%
Operating Cash Flow Growth	-60.26%	-64.15%	-12.03%
Free Cash Flow Firm Growth	-108.46%	-520.40%	43.80%
Invested Capital Growth	-24.47%	-2.41%	-6.11%
Revenue Q/Q Growth	129.11%	14.69%	59.66%
EBITDA Q/Q Growth	5.20%	-11.68%	22.40%
EBIT Q/Q Growth	4.30%	-10.90%	22.04%
NOPAT Q/Q Growth	4.31%	-10.90%	22.02%
Net Income Q/Q Growth	4.54%	-10.69%	12.33%
EPS Q/Q Growth	5.38%	-12.18%	15.79%
Operating Cash Flow Q/Q Growth	16.57%	-24.36%	-31.38%
Free Cash Flow Firm Q/Q Growth	-107.76%	-28.14%	3.33%
Invested Capital Q/Q Growth	-2.95%	0.91%	6.34%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-1,096.60%	-944.44%	-123.29%
Operating Margin	-1,119.41%	-958.27%	-125.93%
EBIT Margin	-1,119.30%	-958.29%	-125.91%
Profit (Net Income) Margin	-1,251.33%	-953.66%	-159.11%
Tax Burden Percent	100.02%	100.00%	100.00%
Interest Burden Percent	111.78%	99.52%	126.36%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-41.62%	-93.44%	-182.71%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-18.37%	-30.94%	-24.55%
Return on Assets (ROA)	-20.54%	-30.79%	-31.02%
Return on Common Equity (ROCE)	-41.62%	-93.44%	-182.71%
Return on Equity Simple (ROE_SIMPLE)	-49.11%	-185.71%	-204.93%
Net Operating Profit after Tax (NOPAT)	-81	-115	-80
NOPAT Margin	-783.59%	-670.79%	-88.15%
Net Nonoperating Expense Percent (NNEP)	-8.02%	-9.69%	-15.44%
Return On Investment Capital (ROIC_SIMPLE)	-30.75%	-130.63%	-113.54%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	356.21%	244.48%	46.44%
R&D to Revenue	863.21%	813.79%	179.49%
Operating Expenses to Revenue	1,219.41%	1,058.27%	225.93%
Earnings before Interest and Taxes (EBIT)	-115	-164	-115
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-113	-162	-113
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	3.36	6.46	5.68
Price to Tangible Book Value (P/TBV)	3.36	6.46	5.68
Price to Revenue (P/Rev)	85.65	33.18	4.41
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	28.86	8.82	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.94	-2.86	-5.28
Leverage Ratio	2.03	3.03	5.89
Compound Leverage Factor	2.27	3.02	7.44
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	0.71	-1.14	-1.25
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	17.16	10.87	9.51
Quick Ratio	16.99	10.62	9.38
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-17	-107	-60
Operating Cash Flow to CapEx	-20,556.70%	-14,969.02%	-37,803.63%
Free Cash Flow to Firm to Interest Expense	-0.82	-5.94	-1.20
Operating Cash Flow to Interest Expense	-3.49	-6.68	-2.70
Operating Cash Flow Less CapEx to Interest Expense	-3.50	-6.72	-2.71
Efficiency Ratios	-	-	-
Asset Turnover	0.02	0.03	0.20
Accounts Receivable Turnover	8.96	4.15	3.83
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	4.71	8.20	46.25
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	40.72	87.97	95.20
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	40.72	87.97	95.20
Capital & Investment Metrics	-	-	-
Invested Capital	-322	-330	-350
Invested Capital Turnover	-0.04	-0.05	-0.27
Increase / (Decrease) in Invested Capital	-63	-7.75	-20
Enterprise Value (EV)	297	151	-18
Market Capitalization	881	569	403
Book Value per Share	$9.22	$3.32	$2.33
Tangible Book Value per Share	$9.22	$3.32	$2.33
Total Capital	262	88	71
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-584	-418	-421
Capital Expenditures (CapEx)	0.36	0.81	0.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-20	-22	1.08
Debt-free Net Working Capital (DFNWC)	421	369	386
Net Working Capital (NWC)	421	369	386
Net Nonoperating Expense (NNE)	48	49	65
Net Nonoperating Obligations (NNO)	-584	-418	-421
Total Depreciation and Amortization (D&A)	2.34	2.38	2.40
Debt-free, Cash-free Net Working Capital to Revenue	-195.30%	-125.38%	1.18%
Debt-free Net Working Capital to Revenue	4,094.01%	2,153.02%	423.37%
Net Working Capital to Revenue	4,094.01%	2,153.02%	423.37%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($4.57)	($6.08)	($5.12)
Adjusted Weighted Average Basic Shares Outstanding	28.17M	26.92M	28.38M
Adjusted Diluted Earnings per Share	($4.57)	($6.08)	($5.12)
Adjusted Weighted Average Diluted Shares Outstanding	28.17M	26.92M	28.38M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	27.93M	26.76M	30.67M
Normalized Net Operating Profit after Tax (NOPAT)	-81	-115	-80
Normalized NOPAT Margin	-783.59%	-670.79%	-88.15%
Pre Tax Income Margin	-1,251.09%	-953.68%	-159.10%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-5.45	-9.09	-2.29
NOPAT to Interest Expense	-3.82	-6.36	-1.61
EBIT Less CapEx to Interest Expense	-5.47	-9.14	-2.30
NOPAT Less CapEx to Interest Expense	-3.84	-6.41	-1.61
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-30.56%	-0.65%

This table displays calculated financial ratios and metrics derived from AnaptysBio's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-93.81%	573.39%	41.65%	184.54%	156.61%	32.27%	422.49%	217.08%	804.67%	378.77%
EBITDA Growth	-392.13%	20.10%	-41.29%	-44.44%	-24.51%	-68.92%	5.05%	-0.44%	40.32%	78.21%
EBIT Growth	-340.25%	16.62%	-39.89%	-44.42%	-27.34%	-62.21%	4.96%	-0.45%	39.67%	77.10%
NOPAT Growth	-338.16%	16.64%	-39.85%	-44.40%	-27.33%	-62.23%	4.95%	-0.44%	39.69%	77.05%
Net Income Growth	-402.58%	18.82%	-22.07%	-22.40%	-11.36%	-59.81%	0.72%	-17.10%	11.95%	48.39%
EPS Growth	-391.67%	21.85%	-20.61%	-30.43%	-19.49%	-70.97%	-3.80%	-14.00%	19.15%	60.38%
Operating Cash Flow Growth	-153.31%	57.77%	-16.91%	-5.23%	-105.52%	-221.47%	-51.63%	16.08%	72.34%	-94.10%
Free Cash Flow Firm Growth	2,250.46%	-79.71%	-84.12%	-81.34%	-102.24%	-148.18%	-211.44%	-66.01%	488.34%	161.54%
Invested Capital Growth	-5,333.45%	-24.47%	-25.90%	-27.05%	-6.40%	-2.41%	3.77%	-12.72%	-12.26%	-6.11%
Revenue Q/Q Growth	6.33%	426.53%	-79.82%	151.82%	-4.10%	171.40%	-20.28%	52.82%	173.60%	43.63%
EBITDA Q/Q Growth	-8.93%	17.57%	-78.19%	9.72%	6.10%	-11.83%	-21.75%	4.50%	44.20%	59.18%
EBIT Q/Q Growth	-6.61%	12.33%	-70.94%	9.60%	6.00%	-11.68%	-0.16%	4.46%	43.55%	57.61%
NOPAT Q/Q Growth	-6.60%	12.35%	-70.95%	9.59%	6.01%	-11.67%	-0.16%	4.45%	43.56%	57.51%
Net Income Q/Q Growth	-2.91%	21.16%	-67.55%	9.97%	6.37%	-13.14%	-4.09%	-6.20%	29.59%	33.69%
EPS Q/Q Growth	-2.61%	21.19%	-69.89%	5.06%	6.00%	-12.77%	-3.14%	-4.27%	33.33%	44.74%
Operating Cash Flow Q/Q Growth	26.50%	39.79%	-129.93%	-3.42%	-43.55%	5.83%	-8.45%	42.76%	52.68%	-560.77%
Free Cash Flow Firm Q/Q Growth	20.47%	-84.24%	-16.15%	17.20%	-114.44%	-239.51%	-93.96%	135.74%	65.00%	-46.20%
Invested Capital Q/Q Growth	-16.81%	-2.95%	-4.01%	-1.58%	2.18%	0.91%	2.26%	-18.99%	2.58%	6.34%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-2,306.88%	-361.15%	-3,188.65%	-1,143.15%	-1,119.32%	-461.22%	-579.44%	-362.10%	-73.84%	-20.99%
Operating Margin	-2,291.80%	-381.51%	-3,231.51%	-1,160.20%	-1,137.19%	-467.91%	-587.84%	-367.52%	-75.81%	-22.43%
EBIT Margin	-2,291.49%	-381.57%	-3,231.80%	-1,160.12%	-1,137.16%	-467.93%	-587.87%	-367.52%	-75.83%	-22.38%
Profit (Net Income) Margin	-2,591.03%	-387.97%	-3,220.89%	-1,151.59%	-1,124.41%	-468.75%	-612.01%	-425.30%	-109.44%	-50.53%
Tax Burden Percent	100.00%	100.09%	100.00%	100.00%	100.00%	99.99%	100.00%	100.02%	100.00%	99.97%
Interest Burden Percent	113.07%	101.59%	99.66%	99.27%	98.88%	100.19%	104.11%	115.70%	144.32%	225.83%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-40.79%	-41.62%	-52.40%	-63.62%	-74.28%	-93.44%	-136.73%	-214.89%	-161.81%	-182.71%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-19.73%	-6.26%	-58.71%	-26.77%	-30.77%	-15.11%	-28.19%	-23.72%	-8.84%	-4.36%
Return on Assets (ROA)	-22.31%	-6.37%	-58.51%	-26.58%	-30.42%	-15.13%	-29.35%	-27.44%	-12.76%	-9.85%
Return on Common Equity (ROCE)	-40.79%	-41.62%	-52.40%	-63.62%	-74.28%	-93.44%	-136.73%	-214.89%	-161.81%	-182.71%
Return on Equity Simple (ROE_SIMPLE)	-48.57%	0.00%	-71.55%	-97.01%	-122.79%	0.00%	-341.79%	-1,721.99%	-196.35%	0.00%
Net Operating Profit after Tax (NOPAT)	-21	-18	-31	-28	-26	-29	-30	-28	-16	-6.77
NOPAT Margin	-1,604.26%	-267.05%	-2,262.06%	-812.14%	-796.03%	-327.53%	-411.49%	-257.27%	-53.07%	-15.70%
Net Nonoperating Expense Percent (NNEP)	-2.60%	-1.37%	-2.35%	-2.21%	-2.09%	-2.54%	-3.21%	-4.18%	-3.71%	-3.58%
Return On Investment Capital (ROIC_SIMPLE)	-	-6.94%	-	-	-	-33.48%	-	-	-	-9.55%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	685.38%	138.18%	787.34%	308.67%	306.57%	114.11%	171.86%	84.72%	35.19%	23.64%
R&D to Revenue	1,706.42%	343.33%	2,544.18%	951.53%	930.62%	453.79%	515.98%	382.80%	140.63%	98.78%
Operating Expenses to Revenue	2,391.80%	481.51%	3,331.51%	1,260.20%	1,237.19%	567.91%	687.84%	467.52%	175.81%	122.43%
Earnings before Interest and Taxes (EBIT)	-30	-26	-44	-40	-38	-42	-42	-40	-23	-9.65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-30	-25	-44	-40	-37	-42	-42	-40	-22	-9.05
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.59	3.36	3.18	3.63	3.96	6.46	12.61	69.30	10.90	5.68
Price to Tangible Book Value (P/TBV)	2.59	3.36	3.18	3.63	3.96	6.46	12.61	69.30	10.90	5.68
Price to Revenue (P/Rev)	160.44	85.65	56.85	41.65	31.87	33.18	26.25	22.47	16.08	4.41
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	28.93	28.86	7.64	3.87	1.57	8.82	10.13	9.55	8.07	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.58	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.48	-1.94	-2.15	-2.34	-2.62	-2.86	-3.75	-5.57	-4.45	-5.28
Leverage Ratio	1.58	2.03	2.26	2.48	2.78	3.03	4.01	5.97	4.79	5.89
Compound Leverage Factor	1.78	2.06	2.25	2.46	2.75	3.04	4.17	6.90	6.91	13.30
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.99	1.19	0.38	0.12	-0.13	-0.25	-0.54	-0.65	0.20	-0.53
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	21.39	17.16	12.21	10.53	10.92	10.87	11.53	9.09	10.23	9.51
Quick Ratio	21.09	16.99	12.09	10.39	10.63	10.62	11.20	8.90	10.08	9.38
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	286	45	38	44	-6.40	-22	-42	15	25	13
Operating Cash Flow to CapEx	-35,494.00%	-6,105.71%	-14,038.86%	-13,373.16%	-22,514.81%	-12,267.50%	-137,974.07%	-64,612.12%	-28,828.57%	-25,350.57%
Free Cash Flow to Firm to Interest Expense	46.68	10.62	8.73	10.18	-1.45	-4.38	-6.68	1.38	1.61	0.77
Operating Cash Flow to Interest Expense	-2.89	-2.51	-5.67	-5.83	-8.23	-6.93	-5.90	-1.95	-0.65	-3.83
Operating Cash Flow Less CapEx to Interest Expense	-2.90	-2.55	-5.71	-5.87	-8.27	-6.98	-5.90	-1.95	-0.66	-3.85
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.01	0.02	0.02	0.02	0.03	0.03	0.05	0.06	0.12	0.20
Accounts Receivable Turnover	4.63	8.96	8.75	6.14	6.73	4.15	5.33	5.00	7.39	3.83
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.05	4.71	5.16	6.34	7.08	8.20	11.67	15.81	28.72	46.25
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	78.89	40.72	41.72	59.47	54.27	87.97	68.45	73.00	49.36	95.20
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	78.89	40.72	41.72	59.47	54.27	87.97	68.45	73.00	49.36	95.20
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-313	-322	-335	-340	-333	-330	-322	-384	-374	-350
Invested Capital Turnover	-0.03	-0.04	-0.04	-0.04	-0.05	-0.05	-0.07	-0.08	-0.16	-0.27
Increase / (Decrease) in Invested Capital	-307	-63	-69	-72	-20	-7.75	13	-43	-41	-20
Enterprise Value (EV)	130	297	82	50	24	151	233	291	462	-18
Market Capitalization	720	881	608	539	477	569	603	685	920	403
Book Value per Share	$9.83	$9.22	$6.84	$5.60	$4.54	$3.32	$1.79	$0.36	$3.07	$2.33
Tangible Book Value per Share	$9.83	$9.22	$6.84	$5.60	$4.54	$3.32	$1.79	$0.36	$3.07	$2.33
Total Capital	278	262	191	148	120	88	48	9.88	84	71
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-590	-584	-526	-489	-453	-418	-370	-393	-458	-421
Capital Expenditures (CapEx)	0.05	0.18	0.18	0.19	0.16	0.28	0.03	0.03	0.04	0.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-14	-20	-30	-33	-24	-22	-15	-24	-25	1.08
Debt-free Net Working Capital (DFNWC)	429	421	401	397	389	369	340	327	405	386
Net Working Capital (NWC)	429	421	401	397	389	369	340	327	405	386
Net Nonoperating Expense (NNE)	13	8.23	13	12	11	13	14	18	17	15
Net Nonoperating Obligations (NNO)	-590	-584	-526	-489	-453	-418	-370	-393	-458	-421
Total Depreciation and Amortization (D&A)	-0.20	1.39	0.59	0.59	0.59	0.60	0.61	0.60	0.60	0.60
Debt-free, Cash-free Net Working Capital to Revenue	-302.56%	-195.30%	-278.66%	-251.89%	-161.93%	-125.38%	-63.34%	-78.34%	-44.28%	1.18%
Debt-free Net Working Capital to Revenue	9,563.05%	4,094.01%	3,754.18%	3,068.45%	2,599.08%	2,153.02%	1,481.24%	1,072.85%	708.04%	423.37%
Net Working Capital to Revenue	9,563.05%	4,094.01%	3,754.18%	3,068.45%	2,599.08%	2,153.02%	1,481.24%	1,072.85%	708.04%	423.37%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.18)	($0.93)	($1.58)	($1.50)	($1.41)	($1.59)	($1.64)	($1.71)	($1.14)	($0.63)
Adjusted Weighted Average Basic Shares Outstanding	28.29M	28.17M	27.95M	26.63M	26.55M	26.92M	26.80M	27.36M	28.89M	28.38M
Adjusted Diluted Earnings per Share	($1.18)	($0.93)	($1.58)	($1.50)	($1.41)	($1.59)	($1.64)	($1.71)	($1.14)	($0.63)
Adjusted Weighted Average Diluted Shares Outstanding	28.29M	28.17M	27.95M	26.63M	26.55M	26.92M	26.80M	27.36M	28.89M	28.38M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	28.43M	27.93M	26.49M	26.55M	26.58M	26.76M	27.32M	27.45M	30.43M	30.67M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-18	-31	-28	-26	-29	-30	-28	-16	-6.77
Normalized NOPAT Margin	-1,604.26%	-267.05%	-2,262.06%	-812.14%	-796.03%	-327.53%	-411.49%	-257.27%	-53.07%	-15.70%
Pre Tax Income Margin	-2,591.03%	-387.62%	-3,220.89%	-1,151.59%	-1,124.41%	-468.80%	-612.01%	-425.22%	-109.44%	-50.54%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.83	-6.11	-10.24	-9.21	-8.52	-8.50	-6.68	-3.68	-1.48	-0.55
NOPAT to Interest Expense	-3.38	-4.28	-7.17	-6.45	-5.96	-5.95	-4.68	-2.58	-1.03	-0.39
EBIT Less CapEx to Interest Expense	-4.84	-6.15	-10.28	-9.25	-8.55	-8.56	-6.69	-3.68	-1.48	-0.57
NOPAT Less CapEx to Interest Expense	-3.39	-4.32	-7.21	-6.49	-6.00	-6.01	-4.68	-2.58	-1.04	-0.40
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-27.45%	-34.72%	-33.82%	-30.56%	-7.64%	0.00%	-0.22%	-0.65%

Frequently Asked Questions About AnaptysBio's Financials

When does AnaptysBio's financial year end?

According to the most recent income statement we have on file, AnaptysBio's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has AnaptysBio's net income changed over the last 2 years?

AnaptysBio's net income appears to be on an upward trend, with a most recent value of -$145.23 million in 2024, rising from -$128.72 million in 2022. The previous period was -$163.62 million in 2023. See where experts think AnaptysBio is headed by visiting AnaptysBio's forecast page.

What is AnaptysBio's operating income?

AnaptysBio's total operating income in 2024 was -$114.95 million, based on the following breakdown:

Total Gross Profit: $91.28 million
Total Operating Expenses: $206.23 million

How has AnaptysBio revenue changed over the last 2 years?

Over the last 2 years, AnaptysBio's total revenue changed from $10.29 million in 2022 to $91.28 million in 2024, a change of 787.3%.

How much debt does AnaptysBio have?

AnaptysBio's total liabilities were at $412.97 million at the end of 2024, a 13.4% increase from 2023, and a 18.6% increase since 2022.

How much cash does AnaptysBio have?

In the past 2 years, AnaptysBio's cash and equivalents has ranged from $35.97 million in 2023 to $123.08 million in 2024, and is currently $123.08 million as of their latest financial filing in 2024.

How has AnaptysBio's book value per share changed over the last 2 years?

Over the last 2 years, AnaptysBio's book value per share changed from 9.22 in 2022 to 2.33 in 2024, a change of -74.7%.

Related Companies

This page (NASDAQ:ANAB) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AnaptysBio (ANAB) Financials

Frequently Asked Questions About AnaptysBio's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AnaptysBio (ANAB) Financials

Annual Income Statements for AnaptysBio

Quarterly Income Statements for AnaptysBio

Annual Cash Flow Statements for AnaptysBio

Quarterly Cash Flow Statements for AnaptysBio

Annual Balance Sheets for AnaptysBio

Quarterly Balance Sheets for AnaptysBio

Annual Metrics and Ratios for AnaptysBio

Quarterly Metrics and Ratios for AnaptysBio

Frequently Asked Questions About AnaptysBio's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools